100 related articles for article (PubMed ID: 1071971)
21. Prostaglandin suppression of mitogen-stimulated lymphocytes in vitro. Changes with mitogen dose and preincubation.
Goodwin JS; Messner RP; Peake GT
J Clin Invest; 1978 Oct; 62(4):753-60. PubMed ID: 701474
[TBL] [Abstract][Full Text] [Related]
22. Immune modulatory effects of indomethacin in melanoma patients are not related to prostaglandin E2-mediated suppression.
Tilden AB; Balch CM
Surgery; 1982 Sep; 92(3):528-32. PubMed ID: 6287658
[TBL] [Abstract][Full Text] [Related]
23. Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patients.
Balch CM; Dougherty PA; Cloud GA; Tilden AB
Surgery; 1984 Jan; 95(1):71-7. PubMed ID: 6229053
[TBL] [Abstract][Full Text] [Related]
24. Nonspecific immunodepression induced by tumor-cell extracts.
Huchet R; Lheritier J
Recent Results Cancer Res; 1976; (56):65-71. PubMed ID: 826992
[TBL] [Abstract][Full Text] [Related]
25. Modulatory effect of prostaglandin E2 on the immune response in mice, with special reference to anti-sperm immunity.
Bratanov K; Tornyov A; Somlev B; Velev B
Int J Fertil; 1986; 31(4):305-10. PubMed ID: 2878901
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of murine tumor growth and prostaglandin synthesis by indomethacin.
Fulton AM; Levy JG
Int J Cancer; 1980 Nov; 26(5):669-73. PubMed ID: 6453846
[TBL] [Abstract][Full Text] [Related]
27. Suppressor cell activity in tumor-bearing mice. I. Dualistic inhibition by suppressor T lymphocytes and macrophages.
Elgert KD; Farrar WL
J Immunol; 1978 Apr; 120(4):1345-53. PubMed ID: 305939
[TBL] [Abstract][Full Text] [Related]
28. Prostaglandin E2-mediated inactivation of various killer lineage cells by tumor-bearing host macrophages.
Parhar RS; Lala PK
J Leukoc Biol; 1988 Dec; 44(6):474-84. PubMed ID: 2973508
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of spleen cell cytotoxic capacity toward tumor by elevated prostaglandin E2 levels in mice bearing Lewis lung carcinoma.
Young MR; Hoover CS
J Natl Cancer Inst; 1986 Aug; 77(2):425-9. PubMed ID: 2942724
[TBL] [Abstract][Full Text] [Related]
30. A syngeneic metastatic tumor model in mice: the natural immune response of the host and its manipulation.
Treves AJ; Cohen IR; Feldman M
Isr J Med Sci; 1976; 12(4-5):369-84. PubMed ID: 1084880
[TBL] [Abstract][Full Text] [Related]
31. In vitro induction of tumor-specific immunity. I. Parameters of activation and cytotoxic reactivity of mouse lymphoid cells immunized in vitro against syngeneic and allogeneic plasma cell tumors.
Wagner H; Röllinghoff M
J Exp Med; 1973 Jul; 138(1):1-15. PubMed ID: 4541509
[TBL] [Abstract][Full Text] [Related]
32. Differential effects of prostaglandin synthetase inhibitors on prostaglandin E2 binding and on prostaglandin- or cholera toxin-induced cyclic AMP accumulation in the rabbit uterus.
Zor U; Koch R; Naor Z
Adv Prostaglandin Thromboxane Res; 1976; 1():331-5. PubMed ID: 187046
[TBL] [Abstract][Full Text] [Related]
33. Immunomodulation by various nitrosoureas and its effect on the survival of the murine host bearing a syngeneic tumor.
Nagarkatti M; Toney DM; Nagarkatti PS
Cancer Res; 1989 Dec; 49(23):6587-92. PubMed ID: 2573418
[TBL] [Abstract][Full Text] [Related]
34. Deficient immunity in head and neck cancer due to excessive monocyte production of prostaglandins.
Berlinger NT
Laryngoscope; 1984 Nov; 94(11 Pt 1):1407-10. PubMed ID: 6593559
[TBL] [Abstract][Full Text] [Related]
35. Subversion of the immune system by tumors as a mechanism of their escape from immune rejection.
Plescia OJ; Grinwich K; Sheridan J; Plescia AM
Prog Biochem Pharmacol; 1978; 14():123-38. PubMed ID: 205882
[No Abstract] [Full Text] [Related]
36. Mice bearing late-stage tumors have normal functional systemic T cell responses in vitro and in vivo.
Radoja S; Rao TD; Hillman D; Frey AB
J Immunol; 2000 Mar; 164(5):2619-28. PubMed ID: 10679101
[TBL] [Abstract][Full Text] [Related]
37. Development of tumor cell resistance to syngeneic cell-mediated cytotoxicity during growth of ascitic mastocytoma P815Y.
Biddison WE; Palmer JC
Proc Natl Acad Sci U S A; 1977 Jan; 74(1):329-33. PubMed ID: 402006
[TBL] [Abstract][Full Text] [Related]
38. Strong prostaglandin associated suppression of the proliferation of human maternal lymphocytes by neonatal lymphocytes linked to T versus T cell interactions and differential PGE2 sensitivity.
Papadogiannakis N; Johnsen SA; Olding LB
Clin Exp Immunol; 1985 Jul; 61(1):125-34. PubMed ID: 2931220
[TBL] [Abstract][Full Text] [Related]
39. Significance of suppressor macrophages for immunosurveillance of tumor-bearing mice.
Fujii T; Igarashi T; Kishimoto S
J Natl Cancer Inst; 1987 Mar; 78(3):509-17. PubMed ID: 2950265
[TBL] [Abstract][Full Text] [Related]
40. Enhancing T lymphocytes from tumor-bearing mice suppress host resistance to a syngeneic tumor.
Treves AJ; Carnaud C; Trainin N; Feldman M; Cohen IR
Eur J Immunol; 1974 Nov; 4(11):722-7. PubMed ID: 4547711
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
